|
Market Closed -
Nasdaq
20:56:55 14/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 69.46 USD | +0.85% |
|
+7.22% | -15.16% |
| 08-12 | Oppenheimer Adjusts PT on Tarsus Pharmaceuticals to $100 From $97, Keeps Outperform Rating | MT |
| 08-07 | Mizuho Adjusts Tarsus Pharmaceuticals PT to $100 From $98, Maintains Outperform Rating | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
- Stock Market
- Stocks
- TARS Stock
- Consensus Tarsus Pharmaceuticals, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
